Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Respiratory Infections
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Respiratory Infections
    Pneumonia and Respiratory Failure from Swine-Origin Influenza A (H1N1) in Mexico - (N Engl J Med)
    Severe Respiratory Disease Concurrent with the Circulation of H1N1 Influenza - (N Engl J Med)
    Measurements Fail to Identify TB Patients Who Can Benefit From Shorter Treatment Course - (DGNews)
    Evolving health effects of Pneumocystis: one hundred years of progress in diagnosis and treatment - (JAMA)
    Variation in antibiotic prescribing and its impact on recovery in patients with acute cough in primary care: prospective study in 13 countries - (BMJ)

    News archive

     Recent webcasts/CME - Respiratory Infections
      Pneumonia in the Elderly: A Review of Severity Assessment, Prognosis, Mortality, Prevention, and Treatment
      Pneumonia in the Elderly: A Review of the Epidemiology, Pathogenesis, Microbiology, and Clinical Features
      Respiratory Synctial Virus (RSV): Prevention Strategies and the Appropriate Identification of Vulnerable Populations
      Emergence of Methicillin-Resistant Staphylococcus aureus
      Pulmonary Complications of Anti-Tumor Necrosis Factor-a Therapy

      Webcasts/CME archive

       Recent cases - Respiratory Infections
        Difficulty in Diagnosing Pulmonary Mucormycosis
        Pneumocystis Jiroveci Pneumonia and Pneumomediastinum in an Anti-Tnfalpha Naive Patient with Ulcerative Colitis
        A Productive Cough
        Acute Facial Purpura in an 82-Year-Old Woman with a Respiratory Tract Infection
        A Rare Case of Community-Acquired Methicillin Resistant Staphylococcus Aureus and Pseudomonas Pneumonia

        Cases archive
          




        my personal edition > respiratory infections > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Once-Daily Telithromycin Effective for Acute Exacerbations of Chronic Bronchitis: Presented at ATS

        By Charlene Laino

        SEATTLE, WA -- May 22, 2003 -- For patients with acute exacerbations of chronic bronchitis (AECB), once-daily telithromycin treatment for 5 days is as effective as commonly used antibiotics taken two to three times daily for 10 days, a new study shows.

        Marcus J. Zervos, MD, of William Beaumont Hospital Research Institute, in Royal Oak, Michigan, United States, presented the findings here on May 19th at the American Thoracic Society International Conference.

        To assess clinical and bacteriologic outcomes 17 to 21 days after treating patients with telithromycin, Dr. Zervos and colleagues analyzed data from three Phase III, multicenter, randomized, double-blind trials.

        They compared outcomes in 615 patients treated with telithromycin 800 mg once daily for 5 days; 160 patients treated with amoxicillin-clavulanic acid 500/125 mg three times daily for 10 days; 191 patients treated with cefuroxime axetil 500 mg twice daily for 10 days; and 282 patients treated with clarithromycin 500 mg twice daily for 10 days.

        The researchers conducted a separate analysis of patients at increased risk due to being age 65 or older, severe pulmonary obstruction, or concomitant disease..

        Patients treated with telithromycin had an 87.1% overall clinical cure rate, defined as a return to preinfection state or improvement in current infection. This compared with 85.6% for comparators groups, the study showed.

        For older patients, the clinical cure rate was 85.1% in the telithromycin group and 84.5% for those treated with other antibiotics.

        The clinical cure rates in patients with one or two risk factors for increased morbidity were 85.9% and 83.6%, respectively, in the telithromycin group versus 84.6% and 83.6%, respectively, for comparators.

        "Telithromycin is consistently effective in patients with acute exacerbations of chronic bronchitis, even in those patients with higher morbidity risk," Dr. Zervos said.

        "With antibiotic resistance [being] a growing problem, an effective and convenient antibiotic treatment that is specifically designed to treat respiratory tract infections would be a valuable therapeutic option for patients and physicians," he said.

        Telithromycin is the first agent in a new class of antibiotics known as ketolides, which deliver a tailored spectrum of activities and require a short-treatment duration for upper and lower respiratory tract infections. In previous clinical trials, the most commonly reported side effects were diarrhea, nausea, and vomiting.

        The drug is currently awaiting U.S. Food and Drug Administration approval.

        Aventis, which manufactures telithromycin, funded the study.


        [Study title: Telithromycin (TEL) Efficacy in Patients with Acute Exacerbations of Chronic Bronchitis (AECB) and Increased Morbidity Risk. Poster B27]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send